DESCRIBEN LA APLICACION DE LA VACUNA BIVALENTE CONTRA EL CANCER DE CUELLO UTERINO
Columnista Experta de SIIC Diane M Harper
en colaboración con
Vierthaler Stephen L, MD, University of Missouri-Kansas, Kansas, EE.UU.
Fecha de aprobación: 23 de junio, 2011
Primera edición en siicsalud:
15 de noviembre, 2011
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/123834
Especialidad principal:
Infectología
Obstetricia y Ginecología
Especialidades relacionadas:
Anatomía Patológica,Atención Primaria,Inmunología,Medicina Familiar,Medicina Interna,Oncología,Pediatría,Salud Pública,
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, Carvalho N, Rotelli C, Teixeira J, Blatter M, Korn A, Quint Wim, Dubin G Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet 364:1757-1765, 2004
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR,Harper DM, et al Prophylactic Quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial, Lancet Oncology 6(6):271-278, 2005
Wiley DJ, Harper DM, Elashoff D, Silverberg MJ, Kaestle C, Cook RL, Heilemann M, Johnson L. How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts, International Journal of STD & AIDS 16(16):203-211, 2005
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial, Obstetrical & Gynecological Survey 60(60):484-484, 2005
Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G on behalf of the HPV Vaccine Study Group. Sustained Efficacy up to 4.5 years of a bivalent L1 virus like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial, Lancet 367:1247-1255, 2006
Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, et al Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18, Vaccine 27(27):5571-5583, 2006
Harper DM, Nieminen P, Paavonen J, Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination., Lancet Infect Dis 10(10):594-559, 2010
Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal K, Harper DM, Markowitz L. Human Papillomavirus and HPV vaccines: a review., Bulletin of the World Health Organization 85(85):719-726, 2007
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GWK, Ferris DG, Steben M, Jones RW, Bryan J, et al Efficacy of a quadrivalent prophylactic human papillomavirus (types 6/11/16/18) L1 virus like particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three clinical trials., Lancet 369(369):1693-1702, 2007
Harper DM, Williams KB. Prophylactic HPV Vaccines: Current Knowledge of Impact on Gynecologic Premalignancies., Discovery Medicine :, 2010
Diane M Harper
Dirección profesional:
7900 Lee's Summit Road - MO 64139, Kansas, EE.UU.
